406 related articles for article (PubMed ID: 23812796)
1. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.
Vieweg WV; Hasnain M; Hancox JC; Baranchuk A; Digby GC; Kogut C; Crouse EL; Koneru JN; Deshmukh A; Pandurangi AK
Psychopharmacology (Berl); 2013 Aug; 228(4):515-24. PubMed ID: 23812796
[TBL] [Abstract][Full Text] [Related]
2. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.
Hasnain M; Vieweg WV
CNS Drugs; 2014 Oct; 28(10):887-920. PubMed ID: 25168784
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
4. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
[TBL] [Abstract][Full Text] [Related]
5. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
6. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
Muzyk AJ; Rayfield A; Revollo JY; Heinz H; Gagliardi JP
Drug Saf; 2012 Jul; 35(7):547-53. PubMed ID: 22702639
[TBL] [Abstract][Full Text] [Related]
7. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
8. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
[TBL] [Abstract][Full Text] [Related]
9. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
11. Cases of drug-induced Torsade de Pointes: a review of Belgian cases in the EudraVigilance database.
Vandael E; Vandenberk B; Vandenberghe J; Willems R; Foulon V
Acta Clin Belg; 2017 Dec; 72(6):385-390. PubMed ID: 28335691
[TBL] [Abstract][Full Text] [Related]
12. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
Chorin E; Wadhwani L; Magnani S; Dai M; Shulman E; Nadeau-Routhier C; Knotts R; Bar-Cohen R; Kogan E; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Stefano C; Chinitz LA; Jankelson L
Heart Rhythm; 2020 Sep; 17(9):1425-1433. PubMed ID: 32407884
[TBL] [Abstract][Full Text] [Related]
13. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
Das B; Rawat VS; Ramasubbu SK; Kumar B
Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.
Letsas KP; Efremidis M; Kounas SP; Pappas LK; Gavrielatos G; Alexanian IP; Dimopoulos NP; Filippatos GS; Sideris A; Kardaras F
Clin Res Cardiol; 2009 Apr; 98(4):208-12. PubMed ID: 19031039
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients.
Al-Azayzih A; Al-Qerem W; Al-Azzam S; Muflih S; Al-Husein BA; Kharaba Z; Kanaan RJ; Rahhal D
Vasc Health Risk Manag; 2024; 20():27-37. PubMed ID: 38318252
[TBL] [Abstract][Full Text] [Related]
16. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.
Wenzel-Seifert K; Wittmann M; Haen E
Dtsch Arztebl Int; 2011 Oct; 108(41):687-93. PubMed ID: 22114630
[TBL] [Abstract][Full Text] [Related]
17. Perioperative torsade de pointes: a systematic review of published case reports.
Johnston J; Pal S; Nagele P
Anesth Analg; 2013 Sep; 117(3):559-564. PubMed ID: 23744954
[TBL] [Abstract][Full Text] [Related]
18. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
[TBL] [Abstract][Full Text] [Related]
19. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports.
Hasnain M; Vieweg WV; Howland RH; Kogut C; Breden Crouse EL; Koneru JN; Hancox JC; Digby GC; Baranchuk A; Deshmukh A; Pandurangi AK
Ther Adv Psychopharmacol; 2014 Jun; 4(3):130-8. PubMed ID: 25057346
[TBL] [Abstract][Full Text] [Related]
20. Personalized, intuitive & visual QT-prolongation monitoring using patient-specific QTc threshold with pseudo-coloring and explainable AI.
Alahmadi A; Davies A; Vigo M; Jay C
J Electrocardiol; 2023; 81():218-223. PubMed ID: 37837739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
